Tarceva Cauases hepatic failure and hepatorenal syndrome
Tarceva (erlotinib) – Cases of hepatic failure and hepatorenal syndrome, including fatalities, have been reported during use of Tarceva Tarceva (erlotinib) Tablets Audience: Oncological healthcare professionals OSI and Genentech notified healthcare professionals that cases of hepatic failure and hepatorenal syndrome, including fatalities, have been reported during use of Tarceva, particularly in patients with baseline hepatic impairment. Patients with [...]
Continue reading...18. November 2008
Epoetin alfa- Preliminary Safety Findings points out to Deaths
FDA has been made aware of preliminary safety findings from a clinical trial conducted in Germany investigating the use of epoetin alfa to treat acute ischemic stroke. The clinical trial utilized doses of epoetin alfa that were considerably higher than the doses recommended for the treatment of anemia as described in the FDA-approved labeling for [...]
Continue reading...27. July 2008
Merck’s Vioxx $4.85 billion payouts to begin in August
Merck & Company will begin funding cto resolve state and federal claims over its painkiller Vioxx. The first payment of $500 million is scheduled for August 6; additional payments will follow. Merck said it met its threshold to make these payouts and waived its right to walk away from last November’s agreement to settle roughly [...]
Continue reading...27. July 2008
FDA recalls Zyprexa
Zyprexa was FDA approved for the short-term treatment of acute manic episodes in bipolar disorder. The worlds best selling schizophrenia drug, Zyprexa sales account for 40% of Eli Lillys $11.08 billion in sales. There have been many questions regarding the popular drug Zyprexa and its safety. Linked to 288 reported Zyprexa diabetes cases, including 23 [...]
Continue reading...27. July 2008
Merck recalls Vioxx
Arthritis drug Vioxx (Rofecoxib) has been voluntarily recalled by Merck & Co Inc. worldwide. The move to pull the COX-2 inhibitor off the market on September 30, 2004 shocked the arthritis world and rocked the stock value of Merck. The Reason The decision to recall Vioxx followed a three year trial, known as APPROVe (Adenomatous Polyp Prevention on [...]
Continue reading...27. July 2008
Arthritis Drug Vioxx Recalled
Arthritis drug Vioxx (Rofecoxib) was recalled by Merck & Co., Inc. The Vioxx recall was voluntarily started by Merck to discontinue the COX-2 inhibitor in September, 2004. Person’s affected by the Vioxx side effects are urged to seek medical and legal help. The Vioxx Recall was prompted after a three year trial known as Adenomatous Polyp [...]
Continue reading...
18. November 2008
0 Comments